Evidence map›Paper›PMID 37855864›Full record

ArticlePsychopharmacology2025

Effects of psilocybin, the 5-HT

Arya Rahbarnia, Zhaoxia Li, Paul J Fletcher

Abstract read
PubMed Publisher
In one paragraph

Article in Psychopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Arya RahbarniaCampbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada. arya.rahbarnia@mail.utoronto.ca.ORCID http://orcid.org/0000-0002-0525-550X
Zhaoxia LiCampbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada.
Paul J FletcherCampbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada.
Centre for Addiction and Mental Health · CA

Funding

CIHR PJT165886
6 · The paper itself

Abstract

rationaleNeuropsychiatric disorders such as depression are characterized in part by attention deficits. Attention is modulated by the serotonin (5-HT) neurotransmitter system. The 5-HT

objectiveUsing the rodent continuous performance task (CPT), we assessed PSI's effect on attention. We also evaluated the impact of 5-HT

methodsIn the CPT, mice learned to distinguish visual targets from non-targets for milkshake reward. Performance was then tested following injections of PSI (0.3, 1, and 3 mg/kg), TCB-2 (0.3, 1, and 3 mg/kg), or M100907 (0.1, 0.3, and 1 mg/kg). Subsequently, drug effects were then evaluated using a more difficult CPT with variable stimulus durations. Mice were then tested on the CPT following repeated PSI injections. Drug effects on locomotor activity were also measured.

resultsIn the CPT, all three drugs reduced hit and false alarm rate and induced conservative responding. PSI also reduced target discrimination. These effects were seen primarily at doses that also significantly reduced locomotor activity. No drug effects were seen on the more difficult CPT or following repeated PSI injections.

conclusionsPsilocybin, TCB-2, and M100907 impaired performance of the CPT. However, this may be in part due to drug-induced locomotor changes. The results provide little support for the idea that psilocybin alters visual attention, or that 5-HT

Indexed as

AttentionBridged Bicyclo CompoundsBridged Bicyclo Compounds, HeterocyclicFluorobenzenesPiperidinesPsilocybinSerotonin 5-HT2 Receptor AgonistsSerotonin 5-HT2 Receptor AntagonistsAnimalsDose-Response Relationship, DrugHallucinogensMaleMethylaminesMicePsychomotor PerformanceReceptor, Serotonin, 5-HT2A(4-bromo-3,6-dimethoxybenzocyclobuten-1-yl)methylamineBridged Bicyclo CompoundsBridged Bicyclo Compounds, HeterocyclicFluorobenzenesHallucinogensMethylaminesPiperidinesPsilocybinReceptor, Serotonin, 5-HT2ASerotonin 5-HT2 Receptor AgonistsSerotonin 5-HT2 Receptor Antagonistsvolinanserin5-HT2AAttentionContinuous performance testLocomotionM100907PsilocybinSerotoninTCB-2

Identifiers

PMID37855864
OpenAlexW4387764874

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.